ALKS Q4 2023 Earnings — Alkermes plc Revenue & Financial Results | Market Cap Arena

ALKSAlkermes plc

$5B

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$377M+23.9% YoY

Gross Profit

$307M81.4% margin

Operating Income

$179M47.3% margin

Net Income

$113M29.9% margin

EPS (Diluted)

$0.66

QoQ Revenue Growth

-0.9%

Cash Flow

Operating Cash Flow

$107M

Free Cash Flow

$90M

Stock-Based Comp.

$26M

Balance Sheet

Total Assets

$2.1B

Total Liabilities

$934M

Stockholders' Equity

$1.2B

Cash & Equivalents

$457M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$377M	$305M	+23.9%
Gross Profit	$307M	$251M	+22.6%
Operating Income	$179M	-$21M	+967.6%
Net Income	$113M	-$28M	+499.2%

Revenue Segments

Product

$705M50%

Vivitrol

$304M22%

Aristada And Aristada Initio

$248M18%

L Y B A L V I

$154M11%